Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LM 101

X
Drug Profile

LM 101

Alternative Names: LM-101 - LaNova Medicines Limited; LM101

Latest Information Update: 01 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LaNova Medicines Limited
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; SIRPA protein inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Phase I Colorectal cancer; Non-Hodgkin's lymphoma; Renal cell carcinoma

Most Recent Events

  • 15 Nov 2023 LaNova Medicines suspends a phase-I/II clinical trials in Solid tumours (Combination therapy, Second-line therapy or greater, Late-stage disease) in China (IV), due to HSP622C-2022001 stability data question (NCT05615974)
  • 15 Nov 2023 LaNova Medicines suspends a phase-I/II clinical trials in Solid tumours (Monotherapy, Second-line therapy or greater, Late-stage disease) in China (IV), due to HSP622C-2022001 stability data question (NCT05615974)
  • 19 Jan 2023 Phase-I/II clinical trials in Solid tumours (Combination therapy, Second-line therapy or greater, Late-stage disease) in China (IV) (NCT05615974)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top